Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1404&sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1403&sort=-other_investigators" }, "data": [ { "type": "Grant", "id": "10689", "attributes": { "award_id": "1R21HL165406-01", "title": "Dissecting SARS-CoV-2 infection in Down syndrome with congenital heart defects using patient-specific iPSCs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23077, "first_name": "Charlene A.", "last_name": "Schramm", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-06", "end_date": "2024-07-31", "award_amount": 234000, "principal_investigator": { "id": 26743, "first_name": "Mingtao", "last_name": "Zhao", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 879, "ror": "", "name": "RESEARCH INST NATIONWIDE CHILDREN'S HOSP", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Down syndrome (DS) is the most common genetic disorder occurring in about 1 in 800 live births, and is characterized by a distinctive facial appearance, intellectual disability, and developmental delays. Gene dosage imbalance in DS patients, primarily caused by an extra copy of chromosome 21 (trisomy 21), is thought to contribute to a broad spectrum of coexisting medical conditions. DS is frequently associated with congenital heart defects (CHDs); approximately 40% of DS patients have some form of CHD, with atrioventricular septal defects (AVSD) being the most prevalent. The swift global spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the ongoing pandemic. Intriguingly, DS patients are more vulnerable to SARS-CoV-2 infection: there is a 4-fold increased risk for COVID- 19-related hospitalization and a 10-fold higher risk for COVID-19-related death compared to patients without DS. Mechanisms by which individuals with DS are more susceptible to COVID-19 are largely unknown. Genetically engineered mice made trisomic for homologous chromosome 16 (MMU16) were developed to study genotype- phenotype correlations in DS. However, because authentic SARS-CoV-2 is unable to infect mice due to the inefficient interaction between the viral S-protein and the mouse orthologue of its receptor, human angiotensin converting enzyme 2 (ACE2), it is not ideal to recapitulate SARS-CoV-2 infection in DS patients using current DS mouse models. In this R21 proposal, we aim to bridge this knowledge gap by dissecting the mechanistic causes of the susceptibility of DS patients to COVID-19 using patient-specific induced pluripotent stem cells (iPSCs). Some genes encoded by chromosome 21 (e.g. transmembrane proteinase serine 2, TMPRSS2) are dysregulated in individuals with DS and have been implicated to have a role in SARS-CoV-2 infection. Our central hypothesis is that upregulation of TMPRSS2 in DS leads to enhanced SARS-CoV-2 infection in the lungs, resulting in an enhanced cytokine surge that increases the severity of COVID-19. In Specific Aim 1, we will elucidate the mechanisms underlying the enhanced cytokine surge in Down syndrome in response to SARS- CoV-2 infection using DS iPSC-derived lung organoids. In Specific Aim 2, we will determine the gene-dosage effect of TMPRSS2 on SARS-CoV-2 infection in DS iPSC-derived cardiac and endothelial cells. It is expected that this project will have a major impact on the understanding of susceptibility of DS patients to SARS-CoV-2 infection using clinically relevant and patient-specific cardiac and lung cells.", "keywords": [ "2019-nCoV", "ACE2", "Alveolar", "Appearance", "Binding", "Biological Assay", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 risk", "COVID-19 severity", "COVID-19 susceptibility", "Cardiac", "Cardiac Myocytes", "Cardiovascular system", "Cell Line", "Cell membrane", "Cell surface", "Cells", "Chromosome 16", "Chromosome 21", "Chronic", "Congenital Heart Defects", "Developmental Delay Disorders", "Down Syndrome", "Endothelial Cells", "Face", "Gene Dosage", "Genes", "Genetic", "Genetic Diseases", "Genetic Materials", "Genetically Engineered Mouse", "Genotype", "Heart", "Hospitalization", "Human", "Immune", "Incubated", "Individual", "Infection", "Integral Membrane Protein", "Intellectual functioning disability", "Knowledge", "Lead", "Live Birth", "Lung", "Medical", "Membrane", "Membrane Fusion", "Mus", "Organ", "Organoids", "Patients", "Pediatric cardiology", "Phenotype", "Predisposition", "Proteins", "RNA Viruses", "Role", "SARS-CoV-2 infection", "Serine Protease", "Serum", "Testing", "Therapeutic", "Tissues", "Transgenic Mice", "Up-Regulation", "Viral", "Virion", "atrioventricular septal defect", "clinically relevant", "cytokine", "high risk", "induced pluripotent stem cell", "induced pluripotent stem cell derived cardiomyocytes", "mouse model", "multidisciplinary", "novel", "pandemic disease", "pathogen", "receptor", "response", "single-cell RNA sequencing", "stem cell biology", "virology" ], "approved": true } }, { "type": "Grant", "id": "10690", "attributes": { "award_id": "1R01GM146962-01", "title": "Four-dimensional Adhesion Frequency Assay for Full Profiling of Receptor-ligand Interactions on Cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23422, "first_name": "ALVIN TIEN-WEI", "last_name": "Yeh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-21", "end_date": "2026-08-31", "award_amount": 379952, "principal_investigator": { "id": 26744, "first_name": "Yuebing", "last_name": "Zheng", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 972, "ror": "", "name": "UNIVERSITY OF TEXAS AT AUSTIN", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This R01 application is responsive to the NIH initiative PAR-19-253 “Focused Technology Research and Development”. Assays for measuring receptor-ligand affinity are valuable in many areas of biomedical research. The “gold standard” surface plasmon resonance assay is limited to recombinant soluble receptors fixed on solid surfaces. The emerging adhesion frequency assay (AFA) techniques can measure the receptor-ligand affinity on their native cellular membranes. However, existing AFA methods can neither resolve the non-uniform distribution of receptors on single cells nor measure the rolling cell adhesion under shear forces. In addition, currentAFAapproaches are generally bulky and low throughput, which require tedious operation. Recently, we have invented a light-driven microrobot (LDM) platform as a non-invasive, programmable, and multimodal cell-manipulation technology. Based on this versatile LDM platform, we propose to develop a paradigm- shift four-dimensional (4D) AFA (i.e., integrated 3D translational AFA and 3D rotational AFA) to overcome these key obstacles in the existing assays. In this R01 project, we will develop and validate our 4D AFA with the following features: (1) measuring receptors on their native cell membrane environments, (2) resolving the non-uniformly distributed receptors on single cells, (3) enabling both translational and rotational AFAs on an integrated platform, (4) investigating cell adhesion under both shear force and tensile force, and (5) allowing on-chip multiplexed cell adhesion measurements. With such features, the proposed 4D AFA has the potential to exceed current lab standards, address unmet needs in the field, and enable high-throughput full profiling of receptor-ligand interactions at sub-cellular resolution. We will validate and improve the 4D AFA performance using well-studied receptor-ligand pairs with variable affinities. We will further package and apply the validated assay to investigate the binding of SARS-CoV-2 virus to angiotensin-converting enzyme 2 receptor and to screen T cells for immunotherapy for cytomegalovirus infection. In this regard, we aim to demonstrate the far-reaching potential of 4D AFA to enable improved research in areas ranging from clinical immunotherapy to fundamental biology.", "keywords": [ "2019-nCoV", "3-Dimensional", "ACE2", "Address", "Adhesions", "Affinity", "Anti-Bacterial Agents", "Antiviral Agents", "Area", "Automation", "Bacterial Infections", "Benchmarking", "Binding", "Biological", "Biological Assay", "Biological Process", "Biology", "Biomedical Research", "Biometry", "Biophotonics", "CD8-Positive T-Lymphocytes", "Cell Adhesion", "Cell membrane", "Cell surface", "Cells", "Cellular Membrane", "Cellular biology", "Clinical", "Complex", "Custom", "Cytomegalovirus Infections", "Devices", "Endothelium", "Environment", "Epithelial Cells", "Event", "Four-dimensional", "Frequencies", "Glycoproteins", "Goals", "Gold", "Hematopoietic", "Human body", "Immunity", "Immunotherapy", "Infection", "Kinetics", "Lasers", "Ligands", "Light", "Major Histocompatibility Complex", "Maps", "Measurement", "Measures", "Methods", "Microfluidics", "Modality", "Optics", "Peptides", "Performance", "Pharmaceutical Preparations", "Process", "Production", "Recombinants", "Research", "Research Personnel", "Resolution", "Rotation", "Site", "Solid", "Stress", "Surface", "Surface Plasmon Resonance", "System", "T-Cell Receptor", "T-Lymphocyte", "Techniques", "Technology", "Translations", "United States National Institutes of Health", "Virus", "Virus Diseases", "austin", "base", "biomaterial compatibility", "cancer cell", "cell killing", "clinical application", "community clinic", "design", "digital", "experimental study", "imaging system", "improved", "insight", "medical schools", "microrobot", "microsystems", "multimodality", "multiplex assay", "novel", "operation", "optical imaging", "pathogen", "programs", "prototype", "receptor", "recruit", "shear stress", "simulation", "technology research and development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "10692", "attributes": { "award_id": "1U01IP001184-01", "title": "RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-30", "award_amount": 2495017, "principal_investigator": { "id": 26748, "first_name": "RICHARD K", "last_name": "ZIMMERMAN", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "– Component A We are applying for RFA components A and D. This abstract refers to Component A. Influenza/pneumonia comprise the 9th and COVID-19 the 3rd leading cause of death in the U.S., with the pandemic entering its 3rd year. Vaccine effectiveness (VE) estimates vary by host factors, viral clade, match to circulating virus, time since vaccination (i.e., waning) and specific vaccine characteristics. PittVax and collaborators have been integral to the US Flu VE Network for 12 years, contributing to influ- enza and COVID-19 VE estimates. Among the current 7 Network sites, PittVax ranks #2 in enrollments, #2 in bloodspot collections, and #1 in follow-up survey completion, while exceeding enrollment goals. PittVax has published >300 peer-reviewed articles in the field. We propose a test-negative case-control design (TND) study among UPMC and federally qualified health center (FQHC) outpatients to determine influenza, COVID-19 and possibly, other respiratory virus VE. Our specific aims are: 1) Determine VE against laboratory-confirmed, medically-attended, acute respiratory in- fections among 1000-1200 outpatients during the influenza season in age groups: 6 mos-18 yrs, 19-49 yrs, and ≥50 yrs, using test negative design in onsite enrollment during respiratory season plus remote enroll- ment outside of influenza season (another 400-900 if COVID-19 persists); 2) provide genetic sequencing on selected specimens for biweekly trends in clade; and 3) determine the annual, population-based burden of influenza and COVID-19 for Allegheny County (Pittsburgh) from the UPMC Health Plan. For determining prior infection for SARS-CoV-2 (e.g., N protein) in the highest proportion of participants, we propose finger- stick bloodspots, supplemented by sera on a subset, for more in-depth studies. The Williams lab, using vali- dated 96-well plate instruments for RT-PCR, which analyzed >10,000 specimens over the last 6 years for influenza, SARS-CoV-2 and other respiratory viruses, will determine presence of infecting viruses. The ex- perienced Harrison lab will perform viral genomic sequencing. We will obtain immunization records from the state’s registry and from UPMC’s and the FQHC’s electronic records. UPMC Health Plan is the largest insurer in Allegheny County and at UPMC in 2021-22, >126,000 county residents were clinically tested for SARS-CoV-2. Annually, UPMC records >5.6 million outpatient visits. Over 1.4 million UPMC acute care visits a year are assessed at Emergency Departments (EDs) and Urgent Care clinics through a common structure and e-record with 305,751 ED visits in 2021 among our four recruiting EDs. UPMC has been rated one of the most wired health systems for 23 years. To address health equity, we add FQHC offices serving mostly persons of color and leadership from the Black Equity Coalition to our multidisciplinary team to assist with culturally competent script/survey development, inclusion of social deter- minants of health data and dissemination of findings with a health equity perspective.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10694", "attributes": { "award_id": "1IK2HX003427-01A2", "title": "Provision of high quality telemental health care during COVID-19 and beyond", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2027-09-30", "award_amount": null, "principal_investigator": { "id": 26751, "first_name": "Samantha L", "last_name": "Connolly", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1521, "ror": "", "name": "VA BOSTON HEALTH CARE SYSTEM", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Background: Telemental health (TMH) via videoconferencing or phone can increase Veterans’ access to mental health (MH) care. TMH can eliminate barriers including travel distance and cost, as well as physical limitations, caregiving responsibilities, and MH symptoms that can make leaving home difficult. Prior to COVID- 19, rates of TMH in VA were low (~9%). There was a dramatic shift towards TMH during COVID-19 to prevent infection, with ~50% of care delivered by phone, ~25% by video, and ~25% in-person. Benefits and drawbacks of phone, video, and in-person care must be considered when choosing a MH care modality. If patients, providers, and/or leadership believe that phone care is equivalent in quality to video and/or in-person, they may be more likely to choose this modality as it often has the fewest barriers to use; however, based on limited evidence, phone care may be lower quality than video and in-person. We need more nuanced analyses regarding: 1) the relative quality of phone, video, and in-person care (e.g., for more complex patients, for psychotherapy sessions versus shorter medication management appointments), and 2) patient preferences. As a clinical psychologist and HSR&D investigator with TMH experience, I am well-positioned to conduct this research. This proposal will provide key methodological training and advance me toward my goal of becoming a leading health services researcher and implementation scientist with expertise in telehealth. Significance/Impact: MH, telehealth, access, and quality of care are all major HSR&D research priorities. The increased use of TMH during COVID-19 has led to a wealth of untapped data through which we can examine the relative quality of TMH care as well as patient preferences across modalities, in order to improve care modality decision-making processes. Results, which will incorporate data from millions of patients and thousands of providers, have the potential to impact delivery of high-quality MH care on a national scale. Innovation: To our knowledge, there has been no published research that: 1) compares the quality and patient preference of phone, video, and in-person MH care, and 2) uses this information to develop and implement evidenced-based strategies to increase video use when clinically effective and preferred by patients. Specific Aims: Aim 1: Examine quality outcomes of phone, video, and in-person MH care (e.g., differences in MH hospitalization rates). Hypothesis: Video care will be equivalent to in-person care and superior to phone care for more complex patients (e.g., history of MH hospitalization, 3+ MH diagnoses) and for psychotherapy appointments. Aim 2: Qualitative interviews with MH patients, providers, and leadership. Research question: What are facilitators/barriers to video use based on stakeholder attitudes, preferences, and decision-making processes, and how do these factors vary between sites with high levels of phone, video, and in-person care? Aim 3: Develop/pilot implementation strategies to increase video use in circumstances where it is clinically effective and preferred by patients. Hypothesis: Implementation strategies will increase video use. Methodology: In Aim 1, I will test for differences in quality outcomes between modalities via a sample of ~2 million Veterans who received MH care between 3/2020-3/2021 using comparative effectiveness research strategies. In Aim 2, I will conduct interviews with key stakeholders to understand facilitators and barriers to video use based on attitudes, preferences and current decision-making processes. In Aim 3, I will synthesize Aim 1 and 2 findings to develop and pilot implementation strategies at one VISN 1 MH site to increase video use in circumstances where it is clinically effective and preferred by patients. Strategies will be targeted at the patient, provider, and/or system levels based on Aim 1 and 2 findings. Next Steps/Implementation: The piloted strategies will be spread to additional MH sites, and ultimately other clinical services, via hybrid implementation-effectiveness trials in subsequent IIRs. Findings will be communicated to MH and Connected Care operational partners to inform the future of VA MH care delivery.", "keywords": [ "Academy", "Address", "Anxiety", "Appointment", "Attitude", "COVID-19", "COVID-19 pandemic", "Caring", "Clinic", "Clinical", "Clinical Services", "Collaborations", "Comparative Effectiveness Research", "Complex", "Data", "Decision Making", "Development", "Diagnosis", "Effectiveness", "Ensure", "Future", "Goals", "Health Services", "Health Services Accessibility", "Health Technology", "Healthcare", "Home", "Hospitalization", "Hybrids", "Infection", "Infection prevention", "Interview", "Leadership", "Medication Management", "Medicine", "Mental Health", "Mental Health Services", "Mentors", "Methodology", "Methods", "Modality", "Outcome", "Outpatients", "Patient Care", "Patient Preferences", "Patients", "Persons", "Positioning Attribute", "Process", "Provider", "Psychologist", "Psychotherapy", "Publishing", "Quality of Care", "Recording of previous events", "Research", "Research Personnel", "Research Priority", "Safety", "Sampling", "Scientist", "Services", "Site", "Suicide prevention", "Symptoms", "System", "Telemental", "Telephone", "Testing", "Time", "Training", "Travel", "Veterans", "Videoconferencing", "Work", "authority", "base", "caregiving", "comparative effectiveness", "connected care", "coronavirus disease", "cost", "design", "effectiveness implementation study", "effectiveness implementation trial", "effectiveness trial", "evidence base", "experience", "health care delivery", "hospitalization rates", "implementation strategy", "improved", "infection risk", "innovation", "pandemic disease", "preference", "prevent", "primary care services", "social stigma", "telehealth" ], "approved": true } }, { "type": "Grant", "id": "10695", "attributes": { "award_id": "1I21RX004092-01A1", "title": "Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2024-09-30", "award_amount": null, "principal_investigator": { "id": 26752, "first_name": "Marianne", "last_name": "Goodman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1533, "ror": "", "name": "JAMES J PETERS VA MEDICAL CENTER", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "At present, 34.6 million people in the United States, and 273,232 Veterans tested or treated in Veteran Affairs facilities contracted COVID-19. While the exact prevalence of Post-Acute COVID-19 Syndrome (PACS) among Veterans is unknown, estimates of psychiatric/neurological PACS using a large global sample of COVID-19 patients (N=236,379) suggest a prevalence of approximately 11,390,400 Americans, and 90,311 Veterans in VA care, with rates likely to increase over time. Moreover, large scale studies suggest up to 35% of individuals experience functional impairment 8 months after COVID-19, and high prevalence of post-infection mental illness including anxiety disorders, depression, and post-traumatic stress disorder. Using longitudinal data from our academic affiliate, Icahn School of Medicine at Mount Sinai’s COVID registry (n≈1200), and local James J. Peters VA’s Clinical PACS program, coupled with our expertise in recovery-based psychotherapy, we are uniquely poised to develop an innovative treatment for Veterans struggling with PACS. Our intervention aims to improve psychological adjustment to PACS symptoms, promote resiliency, and facilitate coping, all of which can impact functional status and quality of life. The PACS-Coping and Recovery (PACS-CR) intervention we aim to develop focuses on psychological adjustment and coping, and augments medical, rehabilitative and neurological treatment for this population. Our approach is based on the CHIME model of personal recovery which includes five overarching processes: 1) Connectedness; 2) Hope and optimism about the future; 3) Identity; 4) Meaning in life; and 5) Empowerment. We will target the CHIME processes using established psychotherapeutic techniques such as skills training, acceptance-based and identity-based principles. Based on adaptations from existing recovery-based and COVID-19 distress group interventions that our team has developed and piloted, we are proposing a treatment framework that consists of a core of twelve 90-minutes sessions (1x/week x 12 weeks) with additional weekly sessions on specialized topics that are optional. We are proposing a treatment development NIH Stage 1A study to develop a Post-Acute COVID-19 Syndrome psychotherapeutic intervention, “PACS Coping and Recovery” (PACS-CR) through an iterative development process while collecting pilot data to assess its acceptability and feasibility. Our treatment development SPiRE will focus on 1) determining the treatment needs of Veterans with PACS, 2) developing the treatment using pilot qualitative data and aided by stakeholder feedback, 3) refining the intervention by three iterative pilots of our groups, testing both in person and telehealth versions. Pre and post measures will be utilized to track functional improvement and the degree to which this recovery-focused intervention has enabled the veterans to engage in meaningful life changes.", "keywords": [ "Activities of Daily Living", "Acute", "Address", "American", "Anxiety", "Anxiety Disorders", "Arthralgia", "COVID-19", "COVID-19 patient", "Cardiovascular system", "Caring", "Chronic", "Climacteric", "Clinical", "Consultations", "Contracts", "Coping Skills", "Coupled", "Data", "Development", "Disease", "Distress", "Education", "Employment", "Epidemiology", "Fatigue", "Feedback", "Fostering", "Future", "Goals", "Headache", "Health", "High Prevalence", "Impairment", "Individual", "Infection", "Intervention", "Interview", "Knowledge", "Leadership", "Life", "Life Style", "Loneliness", "Long COVID", "Longitudinal Studies", "Measures", "Medical", "Memory impairment", "Mental Depression", "Mental Health", "Mental disorders", "Modeling", "Needs Assessment", "Neurologic", "Neurologic Symptoms", "Nutritionist", "Pain", "Pain Disorder", "Participant", "Patients", "Persons", "Phase", "Population", "Post-Traumatic Stress Disorders", "Prevalence", "Process", "Protocols documentation", "Provider", "Psychological adjustment", "Psychotherapy", "Quality of life", "Recovery", "Registries", "Rehabilitation therapy", "Sampling", "Services", "Sleep Disorders", "Sleeplessness", "Specialist", "Symptoms", "Techniques", "Testing", "Time", "United States", "United States Department of Veterans Affairs", "United States National Institutes of Health", "Veterans", "acceptability and feasibility", "arm", "base", "cohort", "common symptom", "coping", "coronavirus disease", "design", "disorder later incidence prevention", "empowerment", "experience", "fitness", "flexibility", "follow-up", "functional disability", "functional improvement", "functional status", "group intervention", "health assessment", "improved", "innovation", "interdisciplinary approach", "medical schools", "neurological rehabilitation", "novel", "optimism", "physical conditioning", "post SARS-CoV-2 infection", "programs", "psychosocial", "pulmonary symptom", "rehabilitation strategy", "resilience", "satisfaction", "skills", "skills training", "sleep health", "symptomatology", "telehealth", "therapy development" ], "approved": true } }, { "type": "Grant", "id": "10698", "attributes": { "award_id": "1U01MD018310-01", "title": "Faithful Response II: COVID-19 Rapid Test-to-Treat with African American Churches", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 1016780, "principal_investigator": { "id": 6100, "first_name": "Jannette Yvonne", "last_name": "Berkley-Patton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10700", "attributes": { "award_id": "75N93021D00035-0-759302200002-1", "title": "Completion of ACTIV-2 Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-11-06", "end_date": "2024-10-31", "award_amount": 82531927, "principal_investigator": { "id": 26756, "first_name": "ANGEE", "last_name": "GREER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1807, "ror": "", "name": "PPD, INC.", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.", "keywords": [ "COVID-19", "COVID-19 therapeutics", "Clinical Research", "Clinical Trials", "Disease Progression", "Immune response", "Infrastructure", "Investigation", "National Institute of Allergy and Infectious Disease", "Outpatients", "Pharmacy facility", "Reporting", "SARS-CoV-2 infection", "Safety", "Services", "Support Contracts", "Therapeutic Intervention", "Viral", "coronavirus disease", "novel therapeutics", "research study", "therapeutic vaccine", "treatment trial" ], "approved": true } }, { "type": "Grant", "id": "10702", "attributes": { "award_id": "5P20GM109091-09", "title": "Synthesis of cannabidiol dimers as potential agents to treat neurological disorders", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 6278, "first_name": "FEDERICO", "last_name": "Bernal", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-08", "end_date": "2024-04-30", "award_amount": 223500, "principal_investigator": { "id": 26757, "first_name": "Francisco", "last_name": "Leon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID pandemic has worsened stress, anxiety, and depression in the US population. Current FDA approved therapeutics for these ailments are only effective in subpopulations, and it is very common for patients to have to attempt multiple regimens to find one that works. Not surprisingly, patients continue seeking alternative remedies for self-treatment, e.g., cannabis. However, regardless of the legalization of cannabis in many states and its widespread usage for these purposes, cannabis is a diverse mixture of hundreds of compounds that widely vary in amount depending on the cannabis source. One active component of cannabis, cannabidiol (CBD), has been individually studied for its medicinal activity. Epidiolex®, a highly purified form of CBD, is FDA approved to treat rare forms of epilepsy. The issue is that CBD – in its natural form – is a non-specific (poly-pharmacological) agent. CBD weakly activates several receptors of the following classes: cannabinoid, opioid, serotonin (5-HT1A, 5-HT2A), orphan-GPR55, adenosine, and TRP receptors, among others. It remains unclear which receptor(s) and signaling pathway(s) are crucial for the positive benefits of CBD. Our long-term goal is to identify and expand novel therapeutics with defined, specific mechanisms of action for neurological/mental disorders. In this light, the overall objective in this application is to create novel CBD dimers that are proposed to be specific to cannabinoid or serotonin receptors. We will assess the hypothesis that CBD homo/heterodimers will enhance the selective binding to cannabinoid and serotonin receptors through bivalent or bitopic binding on dimerreceptors or a single receptor on two sites, respectively. Upon generation of our CBD homo/heterodimer library, we will evaluate their selectivity for the above receptors, and we will also evaluate dimers in a psychoactive receptor panel (NIMH-PDSP). This will position us to build key preliminary data for a competitive NIH application. Development of these novel dimers as chemical biology probes will elucidate the interactions of CBD with serotonin and cannabinoid receptors and the structural details behind these activities. Ultimately, these CBD semisynthetic derivatives have the potential to yield favorable therapeutic indices for the treatment of stress, anxiety, and depression. Results consistent with our hypothesis will have wide-ranging public health implications because of societal interest in CBD despite its poorly understood activities and because of the urgent need for safe, effective therapies. Importantly, if successful, the long-term goal is to move promising compounds into advanced preclinical testing.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10704", "attributes": { "award_id": "1U01MD018316-01", "title": "Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 525000, "principal_investigator": { "id": 24940, "first_name": "Andrew Duane", "last_name": "Plunk", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1806, "ror": "https://ror.org/056hr4255", "name": "Eastern Virginia Medical School", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1806, "ror": "https://ror.org/056hr4255", "name": "Eastern Virginia Medical School", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "10705", "attributes": { "award_id": "1U01MD018306-01", "title": "Leveraging artificial intelligence and social innovation to reduce disparities in COVID-19 testing among African Americans", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 555475, "principal_investigator": { "id": 20638, "first_name": "Tiarney D", "last_name": "Ritchwood", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1404, "pages": 1419, "count": 14184 } } }